Adma Biologics (ADMA) Accumulated Expenses (2011 - 2025)

Adma Biologics' Accumulated Expenses history runs 14 years deep, the most recent figure standing at $172000.0 for Q4 2025.

• Quarterly Accumulated Expenses fell 99.5% year-over-year to $172000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $172000.0 (down 99.5% YoY) and the FY2025 annual result came in at $172000.0, down 99.5% from the prior year.
• Accumulated Expenses was $172000.0 for Q4 2025 at Adma Biologics, down from $4.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $34.1 million in Q4 2024 and bottomed at $172000.0 in Q4 2025.
• A 5-year average of $9.1 million and a median of $3.8 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2021 — Accumulated Expenses jumped 2242.26% — and 2025, when it tumbled 99.5%.
• Adma Biologics' Accumulated Expenses stood at $17.2 million in 2021, then slumped by 75.64% to $4.2 million in 2022, then surged by 684.91% to $32.9 million in 2023, then increased by 3.6% to $34.1 million in 2024, then tumbled by 99.5% to $172000.0 in 2025.
• Business Quant data shows ADMA's Accumulated Expenses at $172000.0 in Q4 2025, $4.5 million in Q3 2025, and $3.1 million in Q2 2025.